Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.
Ainos Inc (NASDAQ: AIMD) delivers innovative healthcare solutions through its pioneering work in low-dose interferon therapeutics and AI-powered diagnostics. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, strategic partnerships, and technological breakthroughs.
Access timely reports on VELDONA clinical trial progress, AI Nose platform deployments, and regulatory milestones. Our curated collection features earnings announcements, research collaborations, and product innovation updates directly from corporate sources. All content undergoes strict verification to ensure accuracy and compliance with financial disclosure standards.
Key focus areas include autoimmune disease research advancements, veterinary medicine applications, and cross-industry implementations of olfactory sensing technology. Regular updates provide insights into how Ainos integrates biologics with artificial intelligence to address critical healthcare challenges.
Bookmark this page for verified updates on Ainos' progress in redefining patient care through science-driven solutions. Visit regularly to stay informed about emerging opportunities in biotech innovation and AI-driven healthcare.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) has signed a Memorandum of Understanding with Merdury Biopharmaceutical Corp. to advance the commercialization of its VELDONA® low-dose interferon treatment. This partnership aims to explore Merdury's potential investment in a Phase 3 clinical trial targeting oral warts in HIV-positive patients. The agreement includes evaluating Merdury's drug development platform and collaborative efforts to identify additional partners for Ainos' drug candidates. Ainos seeks to enhance manufacturing processes and broaden its product portfolio through this strategic alliance, with a focus on delivering value to shareholders.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) announced the issuance of two convertible promissory notes totaling US$3 million to investors. The notes, maturing in two years, bear an interest rate of 6% per annum and can be converted into common shares at US$1.50 each. The unsecured notes aim to strengthen the company's financial position and support its product pipeline. Ainos operates in point-of-care testing and innovative therapeutics, with a focus on low-dose interferon and COVID-19 diagnostics. This offering is exempt from certain U.S. securities registration requirements.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) has signed a Memorandum of Understanding with Taiwanese drug manufacturer Tah-An Chemical & Pharmaceutical Co., Ltd. to explore the feasibility of manufacturing an animal investigational new drug using its VELDONA® formulation. The collaboration aims to begin animal clinical trials in Q1 2023. Ainos will provide technical assistance while Tah-An will handle manufacturing, leveraging its experience since 1966. This partnership is viewed as a significant step in Ainos' commercialization strategy, capitalizing on Tah-An's manufacturing expertise to enhance its product pipeline.
Ainos, Inc. (NASDAQ: AIMD, AIMDW) shared a letter from CEO Chun-Hsien Tsai, reflecting on 2022's challenges and outlining growth strategies for 2023. The company successfully uplisted to Nasdaq in August 2022, enhancing its capital access. Notable projects include Ainos Flora, a non-invasive STI testing device, and VELDONA®, an interferon alpha treatment. Ainos aims to expand its product pipeline, with ongoing clinical studies and potential applications in veterinary medicine. Financially, Ainos reduced its debt ratio significantly from 75% to 6.8% and reported cash of $2.4 million. The company intends to avoid shareholder dilution while pursuing growth opportunities.
Ainos, Inc. (NASDAQ: AIMD) reported a remarkable 384.2% year-over-year revenue increase, totaling $1,757,774 in Q3 2022, driven primarily by robust sales of COVID-19 Antigen Self-Test Kits in Taiwan. Gross profit reached $581,742, with a gross margin of 33.1%. The company's debt ratio significantly improved to 6.8%, down from 75% at the end of 2021. Despite the growth in revenues, a net loss of $7,821,756 was reported. Ainos continues to focus on its innovative product pipeline, including upcoming Phase 2 trials for its VELDONA® oral interferon formulation.
Ainos, Inc. (NASDAQ: AIMD) has received positive FDA feedback on its Biologics License Application (BLA) for treating Sjögren's syndrome following two successful Phase 3 studies. The company is seeking out-licensing partnerships for five new drug candidates based on its low-dose oral interferon-alpha formulation, VELDONA®. These candidates have shown promising results in Phase 2 trials across various conditions, including aphthous stomatitis and influenza. Ainos aims to accelerate the commercialization of VELDONA® through these collaborations, having invested nearly $40 million in its development.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) announced it is pursuing out-licensing opportunities for five new drug candidates of its low-dose oral interferon-alpha formulation, VELDONA. The candidates have successfully completed Phase 2 trials, with plans to accelerate them to Phase 3 and commercialization. The trials demonstrated VELDONA's effectiveness in treating various conditions, including Sjögren's syndrome and influenza. Ainos has invested nearly $40 million in the development of VELDONA and aims to enhance autoimmunity while minimizing side effects compared to high-dose injections.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) announced positive results from its preclinical efficacy study of VELDONA®, a low-dose oral interferon formulation, against the Omicron variant of SARS-CoV-2. The study demonstrated significant stabilization in lung inflammation and recovery in hamsters treated with VELDONA®. The results led to an application for Phase 2 clinical trials in patients with mild COVID-19. The treatment showed a better recovery trend, with no observed mixed-cellular inflammation in the VELDONA® group, compared to 50% in the placebo group.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) has submitted an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA, aimed at treating mild COVID-19 symptoms. The trial will assess VELDONA's efficacy compared to standard care in a multicenter study in Taiwan. If successful, this could enhance treatments for COVID-19 and other viral infections.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) has announced a Master Service Agreement with Swiss Pharmaceutical Co., Ltd. to test, manufacture, and package its VELDONA product candidates. This agreement aligns with Ainos' plans to submit an IND application for a Phase 2 study to the FDA by year-end. Additionally, Ainos is pursuing clinical trials for VELDONA against COVID-19 and has plans for further studies on thrombocytopenia and Sjögren's syndrome in 2023. This partnership aims to enhance Ainos' manufacturing capabilities and streamline its clinical trial preparations.